



## Neuland Q3FY23 income at Rs.270.2 crore, up 13.3% YoY

### EBITDA at Rs. 54.9 crore, up 60.5% YoY

Hyderabad, India, February 13, 2023 - Neuland Laboratories Limited (NLL) (NSE: NEULANLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the third quarter and nine months ended December 31, 2022.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “Over the 9-month period, we recorded a healthy revenue increase led by continued growth in the high margin Specialty and CMS business. Further, the margin improvement reflects the operating leverage playing out. In line with our strategy, we are seeing a significant improvement in the quality of business which is reflected in healthy cashflows. We expect the current business momentum to continue going forward.”

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added “Our investments in Unit 3 as well our emphasis on R&D and Project Execution has resulted in our profitability seeing a marked increase. This was a significant quarter for CMS as we saw the impact of molecules transitioning from development to commercial leading to the highest ever commercial revenues. We expect the CMS business to scale greater heights over the foreseeable future led by steady additions to the pipeline.”

## Financial Summary

Rs. crore

Particulars	Q3FY23	Q2FY23	QoQ Growth (%)	Q3FY22	YoY Growth (%)	9MFY23	9MFY22	YoY Growth (%)
Total Income	270.2	293.9	(8.1)%	238.4	13.3%	785.8	699.4	12.3%
EBITDA	54.9	69.4	(20.9)%	34.2	60.5%	153.3	104.9	46.1%
EBITDA margin (%)	20.3%	23.6%	(330) bps	14.3%	600 bps	19.5%	15.0%	450 bps
PAT	30.4	38.3	(20.6)%	12.7	139.0%	78.6	41.7	88.5%
PAT margin (%)	11.3%	13.0%	(170) bps	5.3%	600 bps	10.0%	6.0%	400 bps
EPS (Basic) Rs.	23.7	29.9	(20.6)%	9.9	139.0%	61.3	32.5	88.5%

## Q3 FY23 Earnings Call

The company will conduct a one-hour Earnings call at **16:30 hrs. IST on Tuesday, February 14, 2023** where the management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please register on the link below:

[Diamond Pass Registration Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

## About Neuland Laboratories Limited

For over 39 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs and has filed over 903+ Regulatory filings in the US (60 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID &GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit [www.NeulandLabs.com](http://www.NeulandLabs.com).

**If you have any questions or require further information, please feel free to contact**

**IR Department at Neuland**

**Tel:** +91 40 6761 1600

**Email:** [ir@neulandlabs.com](mailto:ir@neulandlabs.com)

**Ravi Udeshi, EY IR**

**Email:** [ravi.udeshi@in.ey.com](mailto:ravi.udeshi@in.ey.com)